Bioventus 8/6/2025 Earnings Report

Bioventus EPS Results

• Actual EPS: $0.21
• Consensus EPS: $0.22
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

Bioventus Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bioventus Announcement Details

• Date: 8/6/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Bioventus (NASDAQ:BVS), headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions. In the arena of joint health, Bioventus markets hyaluronic acid‐based injectables, notably DUROLANE®, as well as cold therapy devices under its QUELL® and HEALICOOL® brands to support post-surgical and non-surgical rehabilitation.

Founded in 2012 as a spin-out from Smith & Nephew, Bioventus has expanded its global footprint through strategic acquisitions and product launches. In 2020, the company completed the acquisition of Zimmer Biomet’s biologics business, bolstering its position in the spine and orthopedics markets. Bioventus now operates in more than 40 countries, with commercial activities spanning the United States, Europe, Asia-Pacific and Latin America. Its expansive distribution network and partnerships with hospital systems, orthopedic centers and sports medicine clinics support broad adoption of its non-operative treatment options.

Leadership at Bioventus is spearheaded by President and Chief Executive Officer Eric W. Martins, who joined the company in 2016 with extensive experience in the orthopedic and pharmaceutical industries. He leads a management team focused on driving innovation, expanding clinical evidence and enhancing patient access to orthobiologic therapies. Under this leadership, Bioventus continues to invest in research and development, aiming to introduce new products and strengthen its position as a leader in the non-surgical musculoskeletal market.